ArticleFrontiers in immunology2026
Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gemcitabine (GEM) resistance limits treatment efficacy in bladder cancer (BC). This study identified MAN1B1 as a key driving factor for chemotherapy resistance and malignant progression in BC. Methods: Bulk-RNA datasets GSE190636 and single-cell RNA-seq dataset GSE250523 from GEO. Use limma package to identify differentially expressed genes (DEGs) in the process of GEM resistance, and then perform GO and KEGG enrichment analysis. Screening candidate targets through molecular docking with GEM, and further evaluation through molecular dynamics simulation and GEPIA survival analysis. GSEA analysis is used to explore pathways associated with key genes. Perform single-cell analysis using Seurat, SingleR, Monocle 2, CellChat, and scTenifoldKnk, including cell annotation, pseudo time trajectory, intercellular communication, and virtual knockout. Carry out functional experiments in bladder cancer cell lines, including cell viability, wound healing Transwell, Colony formation and Western blot analysis. Results: Through comprehensive transcriptome analysis and single-cell sequencing, we found that elevated levels of MAN1B1 are associated with poorer clinical outcomes. Computational molecular docking and molecular dynamics simulations indicate the potential binding interaction between MAN1B1 and GEM.This enzyme orchestrates a dual microenvironmental reprogramming by hyperactivating metabolic cascades while simultaneously dampening anti-tumor immune surveillance, predominantly originating from the epithelial compartment to modulate intercellular crosstalk. Functional disturbance experiments showed that knockout of MAN1B1 was associated with decreased cell survival, migration, and invasion, as well as increased sensitivity to GEM, while ectopic expression of MAN1B1 increased cell survival and was associated with enhanced PI3K/AKT/mTOR pathway activity. Conclusions: Our findings uncover the multifaceted regulatory network governing MAN1B1, establishing its utility as an innovative prognostic indicator and an actionable therapeutic vulnerability for overcoming GEM insensitivity in urological oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.